Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients
详细信息 查看全文
- 作者：Rong Zhou1 ; Yuan Yang1 ; Qun Lu ; Jianliu Wang ; wangjianliu@pkuph.edu.cn" class="auth_mail" title="E-mail the corresponding author ; Yali Miao ; Shijun Wang ; Zhiqi Wang ; Chao Zhao ; Lihui Wei
- 关键词：Endometrial cancer ; Endometrial atypical hyperplasia ; Fertility-sparing treatment ; Progestin therapy ; Metformin ; Pcos
- 刊名：Gynecologic Oncology
- 出版年：2015
- 出版时间：December 2015
- 年：2015
- 卷：139
- 期：3
- 页码：424-428
- 全文大小：249 K
文摘
- •
Oral progestin is performed as an effective treatment for CAH/G1EC women desiring to preserve their fertility in China.
- •
Twenty-seven Chinese patients (84.4%) in this study experienced a CR, and 5 (15.6%) failed to respond.
- •
Some patients taking both metformin and progestin were more likely to achieve a CR.